Screener
MoonLake Immunotherapeutics MLTX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $(54,515) | $(36,459) |
| General and administrative | (15,509) | (11,026) |
| Total operating expenses | (70,024) | (47,485) |
| Operating loss | (70,024) | (47,485) |
| Interest expense | (2,269) | (18) |
| Other income, net | 3,208 | 7,097 |
| Loss before income tax | (69,085) | (40,406) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's other operating expenses?
- MoonLake Immunotherapeutics (MLTX) reported other operating expenses of $70.02M in Q1 2026.
- How has MoonLake Immunotherapeutics's other operating expenses changed year-over-year?
- MoonLake Immunotherapeutics's other operating expenses increased by 47.5% year-over-year, from $47.49M to $70.02M.
- What is the long-term trend for MoonLake Immunotherapeutics's other operating expenses?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's other operating expenses has grown at a 55.5% compound annual growth rate (CAGR), from $65.06M to $244.84M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about MoonLake Immunotherapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude